| anti-PD-(L)1 | durvalumab based treatment | sintilimab based treatment |
| cemiplimab | durvalumab alone | sintillimab plus SoC |
| mNSCLC - L1 - all population 5 | | | |
Comparator:
vs Standard of Care (SoC); vs placebo plus SoC;
Risk of bias:
low;
some concerns;
high;
NA;